SynthesisFrontiers in pharmacology2026
Impact of dose and administration schedule on biologic efficacy in chronic rhinosinusitis with nasal polyps: a network meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Chronic rhinosinusitis with nasal polyps (CRSwNP) severely impairs quality of life despite standard surgical and medical therapies. We conducted a network meta-analysis to compare the relative efficacy of biologic agents targeting type 2 inflammation, with a specific focus on how dose and administration frequency influence patient-reported and objective outcomes. Methodology/Principal: A frequentist network meta-analysis was performed across randomized controlled trials evaluating dupilumab, omalizumab, mepolizumab, and benralizumab versus placebo in adults with CRSwNP. Primary outcomes evaluated included sinonasal quality of life (Sino-Nasal Outcome Test-22 [SNOT-22]), objective polyp burden (Nasal Polyp Score [NPS]), and olfactory function (University of Pennsylvania Smell Identification Test [UPSIT]). Interventions were ranked using P-scores. Results: Sixteen randomized controlled trials (4,861 patients) were included. Dupilumab (600 mg loading dose followed by 300 mg every 1-2 weeks) ranked as the most effective regimen for improving quality of life (P-score = 0.907) and provided the greatest enhancement in olfactory function (P-score = 0.006; Standardized Mean Difference [SMD] = 1.91, 95% confidence interval [CI]: 1.24-2.59). Conversely, benralizumab 30 mg administered every 4 weeks was the top-ranked intervention for reducing objective polyp burden (P-score = 0.864). Substantial heterogeneity and significant global inconsistency were observed within the SNOT-22 ( Conclusion: Biologic efficacy in CRSwNP varies distinctly by clinical endpoint and dosing frequency. Dupilumab optimally drives patient-reported quality of life and olfactory recovery, while intensive benralizumab dosing (every 4 weeks) provides the greatest objective reduction in nasal polyp burden. Therapeutic selection should be personalized to align with individual patient phenotypes and clinical priorities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.